Efavirenz - Paperback
$76.21
Skip to product information
Efavirenz - Paperback
$76.21
by Asheesh Singh (Author), Ritu Nigam (Author), Vinayaditya Singh (Author)
Efavirenz was approved by the Food and Drug Administration (FDA) on September 21, 1998, making it the 14th approved antiretroviral drug. Efavirenz (brand name sustiva) is an orally active, non-nucleoside reverse transcriptase inhibitor (nnRTI) that is specific for human immunodeficiency virus, type1 (HIV-1). Efavirenz has a terminal half-life of 52-76 hours after a single dose and 40-55 hours after multiple dosing. It is used together with other antiretrovirals to delay the progression of HIV infection. By doing this, your immune system should improve (increase in CD4+ count) and you will be better protected against infections. Efavirenz does not cure AIDS or completely kill the HIV virus, but helps to prevent further damage by slowing down the production of new viruses. Efavirenz was combined with the popular HIV medication Truvada and approved by the FDA in July of 2006, under the brand name Atripla. Efavirenz is the preferred non-nucleoside reverse transcriptase inhibitor for first-line antiretroviral treatment in many countries.
Number of Pages: 52
Dimensions: 0.12 x 9 x 6 IN
Publication Date: May 13, 2021
Details
This product is crafted with quality materials to ensure durability and performance. Designed with your convenience in mind, it seamlessly fits into your everyday life.
Shipping & Returns
We strive to process and ship all orders in a timely manner, working diligently to ensure that your items are on their way to you as soon as possible.
We are committed to ensuring a positive shopping experience for all our customers. If for any reason you wish to return an item, we invite you to reach out to our team for assistance, and we will evaluate every return request with care and consideration.
